MAP2K7 and cancer: This signaling pathway is often dysregulated (activated) in various types of human cancers, largely due to hyper-activation of PI3K/Akt and Ras/Raf/MEK/ERK signaling, and hence has emerged as an attractive cancer therapeutic target [5–7].